3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Completed
5
Terminated
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Other hematologic neoplasm
2
Lymphoid
2
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
16
Lymphoma, Follicular
7
Waldenstrom Macroglobulinemia
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Neoplasm Metastasis
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Mantle-Cell
2
Lymphoma, B-Cell, Marginal Zone
2
Lymphoma
2
Leukemia, Myelomonocytic, Chronic
2
Leukemia, Myeloid, Acute
2
Leukemia
2
Thrombocytosis
1
Signs and Symptoms, Digestive
1
Recurrence
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Pancreatic Neoplasms
1
Neoplasms
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell
1
Lymphoid Malignancies
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
1
Leukemia, Myeloid, Accelerated Phase
1
Interventions
Rituximab
30
Cyclophosphamide
18
fludarabine phosphate
14
Filgrastim
12
Mycophenolic Acid
11
Antilymphocyte Serum
11
Cyclosporine
10
Whole-Body Irradiation
9
Bortezomib
9
Tacrolimus
8
Radiotherapy
8
Peripheral Blood Stem Cell Transplantation
8
Methotrexate
6
Lenalidomide
6
Cord Blood Stem Cell Transplantation
6
Busulfan
6
Granulocyte Colony-Stimulating Factor
5
venetoclax
4
tanespimycin
4
Polymerase Chain Reaction
4
Methylprednisolone
4
Melphalan
4
Flow Cytometry
4
Etoposide
4
Bendamustine Hydrochloride
4
ublituximab
3
thymoglobulin
3
pembrolizumab
3
ibritumomab tiuxetan
3
fludarabine
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Terminated
×
Lymphoma, B-Cell, Marginal Zone
×
idelalisib
×
Clear all
NCT01732913
2018-11-16
Yosemite
Gilead Sciences
Phase 3
Terminated
295 enrolled
9 charts
NCT01732926
2018-11-16
Bridalveil
Gilead Sciences
Phase 3
Terminated
475 enrolled
9 charts